Drug Trial Radar · NCT04869943
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
52
Actual
Start
Oct 12, 2021
Primary completion
Jan 9, 2024
Study completion Jan 9, 2024
Sponsor
- Lead sponsor
- Veru Inc.Industry
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).
Conditions
- Metastatic Breast Cancer
Interventions
EnobosarmDrug
Oral Enobosarm 9mg per day
ExemestaneDrug
Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the efficacy of Enobosarm in the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).Time frame: Day 120
Locations
54 sites in 4 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona
Banner Health/ Banner MD Anderson Cancer Center
Gilbert, Arizona
The Oncology Insitute of Hope and Innovation
Glendale, California
Marin Cancer Care, Inc.
Greenbrae, California
California Research Institute (CRI)
Los Angeles, California
University of California San Francisco Comprehensive Cancer Center
San Francisco, California
Providence Medical Group
Santa Rosa, California
Rocky Mountain Cancer Centers
Denver, Colorado
Morton Plant Hospital/ BayCare Health System, Inc
Clearwater, Florida
University of Miami- Sylvester Comprehensive Cancer Center
Miami, Florida
Miami Cancer Institute
Miami, Florida
Woodlands Medical Specialists, PA
Pensacola, Florida
Miami Cancer Institute, Plantation MCIP
Plantation, Florida
University Cancer & Blood Center
Athens, Georgia
Blessing Corporate Services
Quincy, Illinois
MBCCOP - LSU Health Sciences Center
Shreveport, Louisiana
Dana-Farber Cancer Institute Breast Oncology
Boston, Massachusetts
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Astera Cancer Care
East Brunswick, New Jersey
Inspira Medical Center Mullica Hill
Mullica Hill, New Jersey
Inspira Medical Center
Vineland, New Jersey
The Lindner Center for Research and Education at the Christ Hospital
Cincinnati, Ohio
Magee-Women's Hospital
Pittsburgh, Pennsylvania
Tidelands Health
Murrells Inlet, South Carolina
Tennessee Cancer Specialists
Knoxville, Tennessee
Baptist Clinical Research Institute
Nashville, Tennessee
Texas Oncology Sammons Cancer Center
Dallas, Texas
Texas Oncology - Tyler
Tyler, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Oncology and Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia
MultiCare Institute for Research and Innovation
Puyallup, Washington
Cancer Care Northwest
Spokane, Washington
MultiCare Institute for Research and Innovation
Spokane, Washington
Wojewódzka Przychodnia Onkologiczna, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
Lodz, Poland
Instytut Centrum Zdrowia Matki Polki
Lodz, Poland
Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
Lublin, Poland
Specjalistyczny Szpital Onkologiczny NU-MED
Maków Mazowiecki, Poland
"Oddział Onkologii Klinicznej i Chemioterapii Europejskie Centrum Zdrowia Otwock"
Otwock, Poland
Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy
Warsaw, Poland
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.